VisEn Fluorescence Molecular Tomography (FMT) scanner

VisEn 荧光分子断层扫描 (FMT) 扫描仪

• 批准号: 8052581
• 负责人: David L Morse
• 金额: $ 29.94万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052581
• 关键词: Adoptive Transfer; Animals; Antibodies; Area; Binding; Biodistribution; Cancer Center; Cells; Clinical; Comprehensive Cancer Center; Congenic Mice; Detection; Development; Diagnostic; Drug Kinetics; Florida; Fluorescence; Fluorescent Probes; Fluorochrome; Funding; Funding Applicant; Grant; Housing; Image; Immunology; Immunotherapy; Institution; Intervention; Laboratories; Ligands; Malignant Neoplasms; Measurement; Minor; Molecular; Molecular Profiling; Monitor; Mouse Strains; Organ; Pharmaceutical Preparations; Prognostic Marker; Proteins; Regimen; Research; Research Personnel; Resolution; Resources; Risk Assessment; Specificity; System; Therapeutic; Therapeutic Studies; Thoracic Oncology; United States National Institutes of Health; biochemical model; cancer imaging; cellular engineering; drug discovery; instrument; instrumentation; molecular imaging; molecular oncology; molecular phenotype; novel; oncology; physical science; pre-clinical; programs; protein expression; public health relevance; response; tomography; tumor; tumor xenograft; uptake

DESCRIPTION (provided by applicant): Funds are requested to purchase a pre-clinical fluorescence molecular tomography (FMT) imaging system to support cancer-related research at the H. Lee Moffitt Cancer Center. This instrument will be housed and operated within the Small Animal Imaging Laboratory, SAIL, situated within the Moffitt vivarium. The Moffitt is the only NIH-designated Comprehensive Cancer Center in the State of Florida, and has recently made a major commitment to developing world class clinical and preclinical cancer imaging capabilities. No other comparable instrument exists in the State of Florida. Thus, this instrument, as all other instruments within SAIL, will be intended to serve as a regional resource. Six major users and 13 minor users have collaborated on this proposal, representing 27 NIH funded grants, including a Program Project in Drug Discovery, a SPORE grant in Thoracic Oncology and a Physical Science Oncology Center grant. These investigators represent five of six research programs within the Cancer Center, including; Drug Discovery, Experimental Therapeutics, Immunology, Molecular Oncology and Risk Assessment, Detection & Intervention. This novel instrumentation will make possible a number of currently inaccessible studies in four distinct areas of research: therapy response assessment, molecular profiling, cell tracking in immunotherapy, and antibody/ligand/nanoagent biodistribution. For therapy response assessment, tumor expression of fluorescent protein expression and the bioactivity of a number of commercially available fluorescent probes can be used to monitor response to experimental drugs and therapeutic regimens. For molecular profiling, novel and available targeted fluorescent probes may be used to identify the expression of key diagnostic and prognostic markers. Cell tracking can be monitored by adoptive transfer of cells engineered to express fluorescent protein into congenic mouse strains and imaging co-localization to fluorescent protein expressing xenograft tumors using multiple channels. Finally, binding specificity, biodistribution and pharmacokinetics of uptake and clearance can be quantitatively assessed for novel targeted molecular imaging agents under development. Public Health Relevance: Funds are requested to purchase a pre-clinical animal imaging instrument for the H. Lee Moffitt Cancer Center, the only NCI designated Comprehensive Cancer Center in the State of Florida. This fluorescence molecular tomography instrument is capable of generating quantitative measurements and high-resolution tomographic images of internally expressed fluorescent proteins, and fluorescent probes associated with internal organs, orthotopic tumor models and biochemical activities. Such an instrument will enable investigators to monitor therapy response, profile molecular phenotypes of cancers, noninvasively track cells during immunotherapy and track the distribution of fluorochrome-conjugated molecules throughout the body. Since this capability is not currently available in the State of Florida, this instrument will serve as a regional resource for investigators at other institutions as well.

描述（由申请人提供）：申请资金用于购买临床前荧光分子断层扫描（FMT）成像系统，以支持H。李莫菲特癌症中心。该仪器将在位于Moffitt动物园内的SAIL小动物成像实验室内放置和操作。Moffitt是佛罗里达州唯一一家NIH指定的综合癌症中心，最近做出了发展世界级临床和临床前癌症成像能力的重大承诺。佛罗里达州没有其他类似文书。因此，这一文书与小岛屿国际法框架内的所有其他文书一样，将作为一种区域资源。 六个主要用户和13个次要用户在这个提案上进行了合作，代表了27个NIH资助的赠款，包括药物发现计划项目，胸部肿瘤学的SPORE赠款和物理科学肿瘤学中心赠款。这些研究人员代表癌症中心六个研究项目中的五个，包括：药物发现，实验治疗，免疫学，分子肿瘤学和风险评估，检测和干预。 这种新的仪器将使一些目前无法在四个不同的研究领域进行的研究成为可能：治疗反应评估，分子分析，免疫治疗中的细胞跟踪和抗体/配体/纳米剂生物分布。对于治疗反应评估，荧光蛋白表达的肿瘤表达和许多市售荧光探针的生物活性可用于监测对实验药物和治疗方案的反应。对于分子分析，新的和可用的靶向荧光探针可用于鉴定关键诊断和预后标志物的表达。可以通过将工程化以表达荧光蛋白的细胞过继转移到同类小鼠品系中并使用多个通道成像共定位到表达荧光蛋白的异种移植肿瘤来监测细胞追踪。最后，结合特异性，生物分布和摄取和清除的药代动力学可以定量评估新的靶向分子成像剂正在开发中。 公共卫生相关性：申请资金用于为H.李莫菲特癌症中心，唯一的NCI指定的综合癌症中心在佛罗里达。该荧光分子断层扫描仪能够生成内部表达的荧光蛋白以及与内脏、原位肿瘤模型和生化活性相关的荧光探针的定量测量和高分辨率断层扫描图像。这种仪器将使研究人员能够监测治疗反应，分析癌症的分子表型，在免疫治疗期间非侵入性地跟踪细胞，并跟踪荧光染料缀合分子在整个身体中的分布。由于佛罗里达州目前尚不具备这一能力，该仪器也将作为其他机构调查人员的区域资源。